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Abstract 
In 2008 Scottish Government issued a new target to reduce Clostridium difficile infection by 
30% in three years. Consequently Scottish hospitals restricted antibiotics with high risk for 
Clostridium difficile and changed from cephalosporins to gentamicin for surgical antibiotic 
prophylaxis. ,QUHVSRQVHWRSK\VLFLDQV¶Foncerns regarding increasing rates of postoperative 
acute kidney injury (AKI), this study aimed to examine postoperative AKI before and after the 
use of gentamicin in surgical prophylaxis. 
The study population was all adults undergoing surgery with antibiotic prophylaxis 
(orthopaedics, urology, vascular, gastrointestinal and gynaecology) between the 1st October 
2006 and 30th September 2010. Post-operative AKI was defined by the Kidney Disease 
Improving Global Outcomes criteria. Study design was an interrupted time series with 
segmented regression analysis. 
12,482 patients were included in the study. In orthopaedic patients, change in policy was 
associated with a 94% increase in AKI (p=0.04, 95% CI 93.8- 94.3%). The antibiotic policy 
change was not associated with significant increase in AKI in any of the other groups. Rates 
of postoperative AKI in vascular surgery were high at 24%, increased in gastrointestinal 
surgery steadily throughout the study period and could only be ascertained in 52% urology 
and 47% gynaecology patients due to lack of creatinine testing. 
The change in antibiotic policy from cefuroxime to flucloxacillin (2 doses of 1g) and single 
dose gentamicin (4mg/kg) was associated with increased rates of AKI in patients undergoing 
orthopaedic surgery within the Tayside region of Scotland and so should be avoided in 
orthopaedic patients in the peri-operative period. Our findings also raise concerns about the 
increasing prevalence of postoperative AKI and of failures to consistently measure 
postoperative renal function. 
 
 
 
 
Introduction 
Reported rates of post-operative acute kidney injury (AKI) vary due to the heterogeneity of 
populations studied. Uncomplicated AKI is associated with a mortality of 10% rising to 50% 
in the context of multi-organ failure and up to 80% if renal replacement therapy (RRT) is 
required1, 2. It was thought that the presence of AKI was a marker of co-existing pathology 
that increased mortality risk but recent reports demonstrate AKI as an independent risk 
factor for mortality3, 4. The increasing incidence of AKI and its long term consequences has 
significant socioeconomic and public health impacts globally5. 
 
Clostridium difficile infection (CDI) is an important healthcare associated infection. Antibiotic 
use increases the risk of CDI for at least three months 6 and short courses of peri-operative 
antibiotic prophylaxis have also been associated with increased risk of CDI particularly in the 
context of an established outbreak7. 
In 2009 Scottish Government issued a new target for all Health Boards to reduce CDI by at 
least 50% over two years8. The Scottish Antimicrobial Prescribing Group also produced 
recommendations for all National Health Service (NHS) boards to restrict the use of 
antibiotics associated with a high risk of CDI9. As part of a widespread antibiotic policy 
change in NHS Tayside; orthopaedic antibiotic prophylaxis was changed from cefuroxime to 
gentamicin and flucloxacillin. Following concerns raised by nephrologists and a small 
uncontrolled study in the Dumfries and Galloway region of Scotland which described an 
increased rate of AKI in patients post orthopaedic surgery following this policy change10, it 
was felt that further investigation of this was required. 
The aim of this study was to use robust methodology, in a larger, population-based study of 
adult patients undergoing orthopaedic implant surgery, to evaluate the effect of the policy 
change on post-operative AKI. It is noteworthy that patients who underwent repair of fracture 
neck of femur (NOF) received co-amoxiclav as antibiotic prophylaxis following the policy 
change due to concerns raised by orthopaedic surgeons with regards to administering 
gentamicin in this particular patient group. This analysis was then extended to evaluate 
postoperative AKI in other surgical specialities (urology, vascular, gastrointestinal and 
gynaecology) that had changed to a gentamicin based regimen. 
 
Results 
Descriptive Data 
In total, 12,482 patients were included in the analysis from 1st October 2006 to 30th 
September 2010. The baseline characteristics of the population are described in Table 1. Of 
note, within the orthopaedic patient group, 36% of the population were prescribed a NSAID 
in the year prior to their operation and 38.5% was prescribed a diuretic. When comparing the 
patients with and without AKI in the orthopaedic group, only increasing Charlson Comorbidity 
index was associated with increased risk of AKI on multivariate analysis, p=0.007 (95% CI 
1.03 to 1.22). There was no difference in the urology patients between patients with or 
without AKI. In the vascular patients, increasing Charlson Comorbidity index was associated 
with increased risk of AKI on multivariate analysis, p=0.03 (95% CI 1.08 to 1.42). In the 
gastrointestinal patients, increasing age and male gender was associated with increased risk 
of AKI, p<0.001 (95% CI 1.03 to 1.07) and p=0.02 (95% CI 0.39 to 0.91). Increasing age was 
associated with increased risk of AKI in the gynaecology patients, p=0.02 (95% CI 1.02- 
1.15). 
 
Characteristics of Patients with Missing Data 
Table 2 shows the percentage of available data for each speciality. There were only 
available biochemistry data pre intervention in 35% of the gynaecology and 58% of urology 
patients and post intervention in 47% of gynaecology patients and 52% of urology patients.  
The majority of missing data were missing post-operative serum creatinines rather than pre-
operatively.  Multivariate analysis of characteristics of included patients versus patients who 
were excluded due to missing data is shown in Appendix table III. When examining the 
characteristics of the patients included with the patients who were excluded due to missing 
data, the orthopaedic patients who were included in the study were older, male gender with 
higher comorbidity scores using the Charlson Comorbidity Index as were the gastrointestinal 
patients.  
 
Results of Interrupted Time Series Analysis 
Orthopaedic Patients 
Figure 1a shows the percentage of AKI Stages 1, 2 and 3 for each study month. Analyses 
using ITS showed that there was a significant increase in AKI after the change in 
prophylactic regimen. After adjustment for use of other nephrotoxic drugs, gender and age, 
only change in policy was significantly associated with increase in AKI with a significant 
change in all levels of severity of AKI after the policy change, (ȕ .30  (95% CI 0.01 to 0.59), 
p = 0.04) for highest serum creatinine post-operatively). This is shown in Table 4. 
Patients who underwent repair of fractured neck of femur (NOF) received co-amoxiclav 
throughout the study period. On analysis of these patients alone, the changes in slope for 
before and after policy change were virtually ]HURȕ -0.106 (95% CI -0.69 to 0.48), p = 0.77 
(Figure 1b).  
 
Other Surgical Specialities 
Results of ITS analysis are shown in Table 3 for urology, vascular, gastrointestinal surgery 
and gynaecological surgery. There is no significant increase in the rates of AKI in these 
surgical specialities related to the policy change. However the baseline rates of AKI in 
vascular surgery are high at 23.2% but do not increase significantly following the policy 
change. In gastrointestinal surgery there was a 1.2% monthly increase in AKI (p=0.29) 
before the policy change, with a 0.6% monthly increase after the change in policy, indicating 
rates that were already rising and slowing after the policy changed. 
 
Orthopaedic Outcome data 
A higher proportion of orthopaedic patients with AKI died within one year of surgery 
compared to those without AKI (20.8% vs 8.2%). Median length of hospital stay was 8 days 
(IQR 5-13) in the patients with AKI compared to 7 days (IQR 5- 13) in those without AKI. 
There were 25 patients with persistent Stage 2 or Stage 3 AKI at seven days post-
operatively. None of these patients underwent renal biopsy. Five died during the admission 
without receiving RRT and 6 received RRT.  All surviving patients recovered their renal 
function to baseline. 
 
 
Discussion 
In this large population based study of over 12,000 patients, we found that increased rates of 
AKI were associated with change in prophylactic antibiotic policy from cefuroxime to 
flucloxacillin and gentamicin in patients undergoing orthopaedic surgery (excluding fracture 
NOF) in the Tayside region of Scotland, UK. The majority of cases had transient Stage 1 AKI 
but there were persisting cases of Stage 2 and 3. This association with the antibiotic policy 
change is strengthened as there was no increase in AKI rates in the fracture neck of femur 
group who received co-amoxiclav as prophylaxis following the policy change. CDI rates fell 
in both of these groups suggesting that the orthopaedic antibiotic prophylaxis policy change 
was not responsible for this reduction. We did not find any association between the change 
in prophylactic antibiotic policy to include gentamicin with AKI in urology, vascular, 
gastrointestinal and gynaecology surgical patients.  
In addition, we identified three areas of concern. Firstly, rates of postoperative AKI in 
vascular surgery were especially high at 23% pre-intervention and 25% in the post 
intervention period; secondly rates of postoperative AKI increased in gastrointestinal surgery 
steadily throughout the study period and thirdly rates of postoperative AKI data could only be 
ascertained in 52% urology and 47% gynaecology patients because of missing 
postoperative serum creatinine data. 
The strengths of our study are that we addressed risks of bias for ITS studies in our analysis 
plan (Appendix table 2), defined the operations using OPCS operation codes (Appendix 
table 1) and used the KDIGO definition of AKI. The limitations of our study are common to all 
non-randomised studies, including potential ascertainment and selection biases. 
Randomised controlled trials are often not appropriate and/or are too expensive to assess 
the effects of global policy change. ITS is the strongest quasi-experimental design to assess 
intervention effects in non-randomized settings. It controls for trends existing before the 
intervention by using multiple points before and after the intervention11, 12. A specific 
limitation of this study was missing pre or post-operative serum creatinines in a large 
proportion of urology and gynaecology patients. The patients who were included were older 
and with greater co-morbidity compared to those who were excluded due to missing 
creatinine data. This could bias the results in these groups in either direction in estimating 
the rates of AKI. In addition, we were unable to adjust for potential effects of medication and 
intra-operative events on AKI rates as this data are not collected electronically. 
 
AKI occurs in 5 to 7.5% of acute care hospital in-patients. Of these cases, 30 to 40% occur 
peri-operatively depending on the surgical setting13, 14. This varies according to surgical 
specialty with the majority of the epidemiological literature in cardiac and vascular surgery15. 
We have shown rates of AKI vary depending on the surgical setting ranging from 6% in 
orthopaedic surgery to 25% in vascular surgery. This suggests that the patients undergoing 
vascular surgery are already at risk of developing AKI. Factors which may contribute to this 
predisposition include age, co-morbidity, use of intravenous contrast for vascular imaging 
and intervention, renovascular disease and the presence of sepsis. Although gentamicin is 
included in the vascular surgery policy it is optional and many patients may not receive it as 
they are deemed ³KLJK ULVN´IRUGHYHORSLQJ$.,ZKLFKmay account for the results in vascular 
patients. In gastrointestinal patients, rates of AKI were increasing prior to the policy change 
with a slower increase following the policy change. Therefore, although rates of AKI are 
higher in the post intervention period, this increase cannot be attributed to the policy change 
so requires investigation into other causes. The large amount of missing data in urology and 
gynaecology with a difference in testing pre and post intervention threatens the validity of 
these data. It is however important to note and concerning that a large number of patients 
who are attending for major surgical procedures are not having their renal function checked 
in the pre or post-operative period particularly as the evolving literature indicates an increase 
in short and long term consequences of AKI in this population. KDIGO AKI guidelines state 
that major surgery is an exposure for AKI and so these patients should have their serum 
Creatinine and urine output measured individualising according to their clinical status16. 
Patients who receive gentamicin prophylaxis are generally undergoing major surgery and so 
we suggest that minimum standard of care should be that they have their bloods checked 
pre-operatively and at least 24 hours post-operatively. 
 
The development of AKI is associated with longer hospital in-patient stays and increased 
mortality13, 14, 17 as well as greater risk of readmission, development and progression of 
chronic kidney disease (CKD) and poorer long term survival18. Epidemiological data has 
shown that survivors of AKI have higher long term mortality rates than those patients who 
survive hospitalization without AKI. This association becomes stronger as the severity of AKI 
increases but is present in patients with small reversible rises in serum creatinine 18. There is 
a lack of therapeutic interventions available once AKI is established. The need for RRT is 
associated with mortality rates of up to 80%, increased hospital stay and significantly 
increased cost. Earlier detection and recognition of AKI to prevent progression and the need 
for RRT is therefore imperative both for short and long term morbidity and mortality as well 
as economically. 
It remains unclear whether gentamicin or flucloxacillin in the doses described, or indeed the 
combination of both, increased the incidence of AKI in this patient group. None of the 
patients in our study underwent renal biopsy and so we cannot ascertain the exact 
mechanism of renal injury. Flucloxacillin is associated with acute interstitial nephritis19 but 
this is a relatively uncommon adverse effect. Gentamicin is a direct tubular toxin and toxicity 
during gentamicin therapy is more commonly observed. Following glomerular filtration some 
gentamicin remains in the lysosomes of the renal proximal tubular epithelium. With either 
prolonged dosing or supra-therapeutic levels, the accumulation of the drug increases; it 
leaks from the lysosomes entering and damaging mitochondria. This leads to tubular 
epithelial cell death and the acute tubular necrosis-like picture typical of gentamicin toxicity20.  
It has been shown that the nephrotoxic potential of gentamicin varies according to the 
population studied. Factors potentially relevant to our population include age, dehydration, 
pre-existing renal impairment and concomitant diuretics and non-steroidal anti-inflammatory 
medication 21. Several recent meta-analyses have shown that the risk of AKI due to 
aminoglycosides is high when used for the empirical treatment of severe gram positive or 
gram negative bacterial infections22-25. Therefore, the KDIGO AKI guideline recommends 
that aminoglycosides should not be used for the treatment of infection unless no suitable, 
less nephrotoxic therapeutic alternatives are available 16. However, concerns regarding anti-
microbial resistance as well as increasing rates of CDI have led to continued widespread 
gentamicin use. In Scotland, the relatively low levels of resistance to aminoglycosides 
amongst key pathogens in the therapeutic context described make them attractive agents. 
 
The orthopaedic population was older with a mean age of 71 years but the median baseline 
serum creatinine was 77µmol/l (IQR 64 to 92) indicating that pre-operative renal function 
was preserved.  36% of the orthopaedic population were prescribed a NSAID in the year 
before surgery and 39% was prescribed a diuretic. However, we adjusted for these factors in 
our analysis.  
 
We have demonstrated that a change in prophylactic antibiotic policy to flucloxacillin (2 
doses of 1g) and single dose gentamicin (4mg/kg) was associated with increased rates of 
AKI in patients undergoing orthopaedic implant surgery. We postulate that this is due to the 
fact that they are a high risk population for developing AKI so greater attention to all 
modifiable risk factors including prophylactic antibiotic choice is vital in the peri-operative 
period in order to reduce AKI risk in this vulnerable patient group. The findings of this study 
has led to a change in the national antibiotic policy recommendation for orthopaedic surgical 
prophylaxis in Scotland and so demonstrating the importance of measuring unintended 
consequences of healthcare interventions. It is therefore planned for this study to be 
repeated across other health boards in Scotland. We have also highlighted that rates of AKI 
in vascular surgery are high and AKI is rising in gastrointestinal surgery. Furthermore, it is 
concerning that there was a lack of testing for AKI in urology and gynaecology surgery. 
Greater awareness and increased testing for this potentially reversible condition is vital. 
 
Methods 
All adults over 18 years resident in or who died in the NHS Tayside region and who 
underwent surgical procedures where the revised surgical prophylaxis policy included 
gentamicin as part of a  prophylactic antibiotics regime (Table 2) between 1st October 2006 
and 30th September 2010 were included. This study period encompassed two years before 
and after the change in the antibiotic policy. Cases were identified by the operation 
procedure codes (OPCS) from hospital admissions data (Appendix Table1). Table 1 shows 
the recommended antibiotics and doses before and after the policy change. The primary 
definition of post-operative renal impairment used was the Kidney Disease Improving Global 
Outcomes (KDIGO) criteria16. This was applied using baseline serum creatinine as pre-
measurement (most recent prior to surgery) and maximal serum creatinine during the first 
seven post-operative days as post measurement. Patients with post-operative AKI were 
classified according to their most severe degree of AKI. Stage 1 was defined as increase in 
serum creatinine of >26.4µmol/l or increase to 150% to 200% of baseline. Stage 2 was an 
increase in serum creatinine to 200% to 300% of baseline value and stage 3 was an 
increase in serum creatinine to more than 300% of baseline or serum creatiniQHRI
354µmol/l or initiation of RRT. 
 
Data were linked using the Health Informatics Centre (HIC)26, University of Dundee. HIC 
enables anonymised health record linkage from the population of Tayside (400,000), 
Scotland, using a unique identifying Community Health Index (CHI) number. Data were 
linked between the following relevant datasets: Scottish Morbidity Record of hospital 
admissions (SMR01) and OPCS coded procedures; laboratory results and medicines 
dispensed by community pharmacies. 
Age, to the nearest year in the year of surgery and gender was obtained from the CHI 
register and social deprivation from SIMD (Scottish Index of Multiple Deprivation, linked to 
post code from CHI register).  
A Charlson Comorbidity Index (CCI)27 was calculated for each patient from hospital 
discharge codes  and the number of dispensed prescriptions from community pharmacies in 
the previous year was applied as an additional measure of comorbidity. Exposure to 
medicines in the previous year that predispose to renal impairment (non-steroidal anti-
inflammatory drugs (NSAIDs), Cox-2 inhibitors, ACE-inhibitors, Angiotensin-II receptor 
antagonists, diuretics, and beta-blockers) was ascertained from dispensed prescribing data.  
Baseline renal function was obtained from the laboratory database. This was the most 
recent, pre-operative serum creatinine and could include pre-operative samples taken during 
the current admission for elective surgery but patients undergoing emergency surgery may 
have AKI on admission to hospital as a result of trauma. We therefore used the most recent 
serum creatinine prior to admission for emergency patients to distinguish chronic kidney 
disease from AKI. Only patients with pre and post-operative creatinine measurements could 
be included, so we measured and reported the completeness of data in each group. Patients 
on renal replacement therapy (RRT) were excluded from the analysis. 
 
Statistical Methods 
Data from each surgical speciality (orthopaedics, urology, vascular surgery and obstetrics 
and gynaecology) were analysed separately. The design was an interrupted time series 
(ITS) study with segmented regression analysis28 using 24 monthly time points before and 
after the intervention in October 2008. The analysis plan included information that addressed 
the common risks of bias in ITS studies (Appendix table I). The monthly rates of AKI were 
defined by the number of cases of each AKI stage as a proportion of all those aged 18 or 
older undergoing surgery in each month. Rates were plotted over time for descriptive 
purposes and the functional form of the relationship pre and post intervention assessed with 
splines. Rates were analysed using multiple linear regression if the functional form was 
linear. Where monthly rates were not normally distributed, log transformation was used in 
the linear regression models to conform to the statistical criterion of normal distribution of 
residuals. All models were tested for autocorrelation using the Durbin-Watson statistic29. 
Multivariate analyses including age, gender, nephrotoxic drugs and co-morbidity were 
carried out only when there was a significant change in AKI post intervention. Data for 
chronic nephrotoxic medication use were adjusted at an aggregate level. Poisson regression 
analysis was used when there were no or few cases for certain months. In Poisson 
regression, the outcome variable is in the form of counts or number of cases and the natural 
log of the denominator (total number of operations) were included in the model as an offset.  
Analyses were carried out in IBM SPSS (v21) and SAS (v 9.2.1). 
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Figure Legends 
 
Figure 1a: Percentage of AKI (adjusted) Stages 1, 2 and 3 for each month (excluding NOF).  
 
Figure 1b: Percentage of AKI ±stage 1, 2 and 3 for each month in fracture NOF cases. The 
most severe AKI stage was used for this analysis. 
 
 
Table 1: Descriptive data for other surgical specialities 
 
 Orthopaedics Urology Vascular Surgery Gastrointestinal Surgery Gynaecology 
Intervention Before After Before After Before After Before After Before After 
Recommended 
Antibiotics 
Cefuroxime 
(1.5g) 
Flucloxacillin 
(1g) x2 + 
gentamicin 
(4mg/kg) 
Co-amoxiclav 
(1.2g) 
Gentamicin 
(4mg/kg) 
Co-amoxiclav 
(1.2g) 
Flucloxacillin 
(1g) x2 + 
metronidazole 
(500mg) +/- 
gentamicin 
(4mg/kg) 
Co-amoxiclav 
(1.2g) 
Metronidazole  
(500mg) 
+ gentamicin 
(4mg/kg) 
Co-
amoxiclav 
(1.2g) 
Metronidazole 
(500mg) 
 + gentamicin 
(4mg/kg) 
Number of patients 3674 3992 421 402 358 362 1599 1672 176 227 
Mean age (SD) 71.2 (13.5) 70.7 (13.9) 71.4 (12.5) 70.0 (13.1) 70.0 (11.3) 69.0 (12.9) 62.1 (15.9) 61.8 (16.3) 54.9 (13.7) 53.5 (13.7) 
Baseline Serum 
Creatinine (µmol/l)*  
median (IQR)  
79.0 
(66.0, 94.0) 
75.0  
(62.0, 90.0) 
92.0  
(77.0, 114.0) 
90.0  
(74.0, 114.0) 
89.5  
(75.0, 113.0) 
84.0  
(67.0, 108.0) 
75.0 
(62.0, 89.0) 
71.0  
(60.0, 85.0) 
71.0  
             
(61.0, 83.0) 
65.0 
(58.0, 75.0) 
Gender 
(%) 
F 2359 (64.2) 2451 (61.4) 101 (24.0) 87 (21.6) 117 (32.7) 241 (67.3) 953 (57.0) 902 (56.4) 176 (100) 227(100) 
M 1315 (35.8) 1541 (38.6) 320 (76.0) 315 (78.4) 241 (67.3) 234 (64.6) 719 (43.0) 697 (43.6) 0 0 
SIMD (%) 1 ± 3 706 (19.4) 788 (20.0) 88 (21.2) 108 (27.2) 111 (31.2) 104 (29.0) 402 (24.4) 352 (22.4) 40 (23.0) 59 (26.0) 
4 - 7 1616 (44.5) 1716 (43.6) 176 (42.4) 161 (40.6) 143 (40.2) 151 (42.1) 682 (41.4) 676 (43.1) 70 (40.2) 100 (44.1) 
8 ± 10  1311 (36.1) 1429 (36.3) 151 (36.4) 128 (32.2) 102 (28.7) 104 (29.0) 565 (34.3) 541 (34.5) 64 (36.8) 68 (30.0) 
CCI  
(%) 
 
Low (0 or 1) 3494 (95.1) 3774 (94.5) 206 (48.9) 230 (57.2) 244 (68.2) 236 (65.2) 951 (59.5) 1040 (62.2) 122 (69.3) 152 (67.0) 
Medium (2) 121 (3.3) 145 (3.6) 185 (43.9) 128 (31.8) 68 (19.0) 73 (20.2) 432 (27.0) 425 (25.4) 45 (25.6) 65 (28.6) 
High (3+) 59 (1.6) 73 (1.8) 30 (7.1) 44 (10.9) 46 (12.8) 53 (14.6) 216 (13.5) 207 (12.4) 9 (5.1) 10 (4.4) 
 
 
Table 2: Completeness of creatinine data 
 
 
Operation Pre policy change Post policy change Chi-square (p-value) Pre-operative Post-operative Pre & Post 
 Number of cases with creatinine data (%)  
All Orthopaedic NOF 3674 (81) 4009 (82)  3.68 (0.05) 8883 (94.5) 7917 (84.2) 7698 (81.9) 
Urology 421 (58) 402 (52) 4.38 (0.04) 1396 (92.9) 828 (55.1) 823 (54.8) 
Vascular 358 (89) 362 (86) 2.00 (p=0.16) 798 (96.8) 727 (88.2) 720 (87.4) 
Gastrointestinal 1599 (78) 1672 (78) 0.50 (p=0.48) 4089 (97.6) 3315 (79.2) 3271 (78.1) 
Gynaecology 176 (35) 227 (47) 12.76 (<0.001) 927 (94.2) 423 (43.0) 403 (41.0) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Summary table of results in all surgical specialties 
 
 
 Fracture neck of femur Other orthopaedic 
implant surgery 
Urological surgery Vascular surgery Gastrointestinal Gynaecology 
Post-operative AKI1 
pre-policy change (%) 
104(15.0) 186 (6.2) 49(11.6) 83(23.2) 118(7.4) 
8(4.5) 
Post-operative AKI1 
post-policy change (%) 
94(14.8) 361(10.8) 63(15.7) 91(25.1)           204(12.2) 
             9(4.0) 
%  change in AKI (post 
versus pre-policy 
change) (95% CI) 
-9.6 
(-10.2 to -9.1) 
+94 
(93.8 to 94.3) 
+28.6 
(26.8 to 30.4) 
+9.6 
(8.9 to 10.3) 
+72.9 
(72.2 to 73.6) 
             +12.5 
(4.4 to 20.6) 
Incidence rate ratio 
(95%CI) post versus 
pre-policy change 
0.99 
(0.75-1.30) 
1.72 
(1.43-2.05) 
1.35  
(0.93-1.95) 
1.08 
 (0.80 - 1.45) 
1.65  
(1.32 -  2.07) 
0.87  
(0.34-2.26) 
Segmented regression analysis, point estimates (ß) and p values 
Variable ß p ß p ß p ß p ß p ß p 
Pre-intervention 
slope 
(95% CI) 
0.17 
(-0.24- 0.58) 
 
0.41 
0.08 
(-0.12 -0.28) 
0.40 
-0.00 
(-0.01- 0.02) 
0.997 
0.02 
(-0.01- 0.04) 
0.18 
0.01 
(-0.01- 0.04) 
0.29 
         
        -0.04 
  (-0.13- 0.05) 
0.35 
Change in level 
(95% CI) 
 
        -3.68 
 
(-11.74 -4.37) 
0.36 
     -1.65 
(-5.45- 2.16) 
0.39 
-0.01 
(-0.24- 0.22) 
0.91 
-0.03 
(-0.50- 0.45) 
0.92 
-0.14 
(-0.52- 0.25) 
0.49 
 
-0.48 
 (-2.42- 1.46) 
0.63 
Change in slope 
(95% CI) 
-0.11 
(-0.69 -0.48) 
0.77 
       0.30 
(0.01 -0.59) 
0.04 
0.01 
(-0.01 - 0.03) 
0.16 
-0.03 
(-0.07- 0.01) 
0.11 
0.01 
(-0.02- 0.03) 
0.68 
 
0.04 
 (-0.09- 0.16) 
0.55 
 
1% patients with AKIN stages 1-3 (at least 150% increase in SCr) 
The incidence rate ratio is calculated as:  C-post/T-post 
C-pre/T-pre 
C-post: number of cases in the post-operative period; T-post: number of person years at risk in the post-operative period 
C-pre: number of cases in the pre-operative period; T-pre: number of person years at risk in the pre-operative period 
 
 
Table 4: ITS of monthly percentage of AKI in orthopaedic surgery using pre vs. highest post-operative Creatinine measurement - excluding 
cases with NOF fracture 
 
Variables ȕ (95% Confidence Interval) p 
Time 0.08 (-0.12 to 0.28) 0.40 
Intervention (0 = pre policy change , 1 = post policy change) -1.65 (-5.45 to 2.16) 0.39 
Time after intervention 0.30 (0.01 to 0.59) 0.04 
Percentage of males (+1%) -0.07 (-0.30 to 0.16) 0.52 
Mean age (+1 year) 0.09 (-0.69 to 0.88) 0.81 
Percentage of Beta-blockers (+1%) -3.85 (-8.24 to 0.54) 0.08 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
